TG Therapeutics (TGTX) shares tumbled 5.71% in pre-market trading on Monday, August 4, 2025, despite the company reporting positive second-quarter financial results and raising its revenue guidance for its drug Briumvi.
The biotechnology company announced its Q2 2025 financial results early Monday, reporting product revenue of $138.843 million and a net income of $28.187 million. Additionally, TG Therapeutics raised its revenue guidance for Briumvi, its flagship multiple sclerosis treatment.
Despite these seemingly positive developments, investors appear to be reacting negatively, possibly indicating that the results or the raised guidance fell short of market expectations. The pre-market plunge suggests that Wall Street may have been anticipating even stronger performance or more optimistic forecasts from the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.